1. Home
  2. GRFS vs DNTH Comparison

GRFS vs DNTH Comparison

Compare GRFS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$8.48

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$92.69

Market Cap

5.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRFS
DNTH
Founded
1940
2015
Country
Spain
United States
Employees
25247
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
5.1B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
GRFS
DNTH
Price
$8.48
$92.69
Analyst Decision
Hold
Strong Buy
Analyst Count
2
13
Target Price
$10.15
$121.00
AVG Volume (30 Days)
649.3K
858.8K
Earning Date
07-28-2022
05-11-2026
Dividend Yield
1.63%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,036,000.00
Revenue This Year
$4.69
N/A
Revenue Next Year
$6.49
$29.48
P/E Ratio
$18.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.90
$16.77
52 Week High
$11.14
$96.50

Technical Indicators

Market Signals
Indicator
GRFS
DNTH
Relative Strength Index (RSI) 53.66 67.84
Support Level $8.27 $33.94
Resistance Level $9.08 N/A
Average True Range (ATR) 0.21 4.33
MACD 0.09 -0.24
Stochastic Oscillator 67.73 79.15

Price Performance

Historical Comparison
GRFS
DNTH

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: